Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2016 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Present at PIONEERS 2016 by Joseph Gunnar & Co. Thursday, May 5, 2016

FRAMINGHAM, MA--(Marketwired - Apr 26, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
April 25, 2016 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Receives Notice of Allowance for Patent Covering Systemic Applications for Self-Assembling Peptides

FRAMINGHAM, MA--(Marketwired - Apr 25, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
April 21, 2016 18:14 ET | Source: Carter BloodCare

Carter BloodCare one of only two U.S. laboratories to receive AABB accreditation for molecular testing for red cell antigens

DALLAS and FORT WORTH, Texas, April 21, 2016 (GLOBE NEWSWIRE) -- Carter BloodCare, a blood center serving 200 medical facilities in 50-plus Texas counties, announces it is only the second blood center...
April 11, 2016 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Notice of Allowance for Method of Use Patent Covering Uses of Self-Assembling Peptides

FRAMINGHAM, MA--(Marketwired - Apr 11, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
April 05, 2016 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Notice of Allowance for Composition-of-Matter Patent Covering Self-Assembling Peptides

FRAMINGHAM, MA--(Marketwired - Apr 5, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
March 22, 2016 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Obtains Favorable Safety Data for AC5 Surgical Hemostatic Device(TM) in Skin Irritation Testing in Humans

FRAMINGHAM, MA--(Marketwired - Mar 22, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), reports...
March 14, 2016 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Reports Favorable Results for AC5 Surgical Hemostatic Device in Biocompatibility Testing Required for CE Mark

FRAMINGHAM, MA--(Marketwired - Mar 14, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), has obtained...
March 10, 2016 08:20 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Present at the 28th Annual Roth Capital Conference on Tuesday, March 15, 2016

FRAMINGHAM, MA--(Marketwired - Mar 10, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
March 09, 2016 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Receives ISO 13485 Certification for AC5

FRAMINGHAM, MA--(Marketwired - Mar 9, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), today announces...
March 07, 2016 07:57 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Clinical Trial Actively Enrolling Patients and Providing Investigational Treatment

FRAMINGHAM, MA--(Marketwired - Mar 7, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), has initiated...